Tecentriq receives FDA approval for alveolar soft part sarcoma

Otis Brawley looks back on a year of great science and greater challenges

In a year that brought us new KRAS-inhibiting drugs, deepened our understanding of HER2 in breast cancer, and highlighted new potential for mRNA vaccines, the cancer field was also rocked by uncertainty of the future of research funding, equity in cancer delivery, and the integrity of review at FDA.

December 31, 2025

Cancer Policy

Angelo de Claro named acting director of FDA Oncology Center of Excellence

Angelo de Claro was named acting director of the FDA Oncology Center of Excellence, following Richard Pazdur’s departure from that position—and the agency (The Cancer Letter, Dec. 5, 2025).

Ohio State to be awarded funding to optimize sarcoma treatment

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has been approved for research funding by the Patient-Centered Outcomes Research Institute to study whether adding chemotherapy before standard treatment with immunotherapy, radiation, and surgery for certain sarcomas will reduce the risk of the cancer returning.

December 19, 2025

Vol.51 No.46

Drugs & Targets

FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer

FDA has approved rucaparib (Rubraca) for adults with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer previously treated with an androgen receptor-directed therapy.

December 19, 2025

Vol.51 No.46

Drugs & Targets

FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma

FDA and OS Therapies held a Type C meeting regarding the phase IIb human clinical trial of OST-HER2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma.

December 19, 2025

Vol.51 No.46

Drugs & Targets

FDA awards National Priority Voucher to Tecvayli+Darzalex based on phase III study results

FDA has awarded a National Priority Voucher to teclistamab (Tecvayli) in combination with daratumumab (Darzalex) for relapsed/refractory multiple myeloma. This brings the total number of products receiving an award under the Commissioner’s National Priority Voucher pilot program to 16.

December 19, 2025

Vol.51 No.46

Tecentriq receives FDA approval for alveolar soft part sarcoma

YOU MAY BE INTERESTED IN

Otis Brawley looks back on a year of great science and greater challenges

Angelo de Claro named acting director of FDA Oncology Center of Excellence

Ohio State to be awarded funding to optimize sarcoma treatment

FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer

FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma

FDA awards National Priority Voucher to Tecvayli+Darzalex based on phase III study results

Renew today!

Subscriber content

Never miss an issue!

Login